Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).
Sabrina JotschkeSusann SchulzeNadja JäkelBeatrice Ludwig-KrausRobby EngelmannFrank Bernhard KrausChristina ZahnNicole NedlitzGabriele Prange-KrexJohannes MohmBettina PeuserMaik SchwarzClaudia SpohnTimo BehlendorfMascha BinderChristian JunghanssSebastian BöttcherHaifa Kathrin Al-AliPublished in: Cancers (2022)
Evidence of vaccine-elicited humoral and/or cellular immunogenicity in most patients is provided. Both humoral and cellular responses are crucial to determine which patients will generate/maintain immunity. The findings have implications on public health policy regarding recommendations for SARS-CoV-2 booster doses.
Keyphrases
- immune response
- sars cov
- public health
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- prognostic factors
- peritoneal dialysis
- dendritic cells
- mental health
- randomized controlled trial
- acute myeloid leukemia
- patient reported outcomes
- inflammatory response
- cross sectional
- clinical practice
- respiratory syndrome coronavirus